{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T16:01:15Z","timestamp":1782316875528,"version":"3.54.5"},"reference-count":28,"publisher":"Informa UK Limited","issue":"8","content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Expert Review of Hematology"],"published-print":{"date-parts":[[2025,8,3]]},"DOI":"10.1080\/17474086.2025.2522295","type":"journal-article","created":{"date-parts":[[2025,6,17]],"date-time":"2025-06-17T10:52:39Z","timestamp":1750157559000},"page":"633-648","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":1,"title":["Efficacy and safety of pyruvate kinase activator in treating hemolytic anemias: a systematic review"],"prefix":"10.1080","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3575-5764","authenticated-orcid":false,"given":"Syed Hassan","family":"Ahmed","sequence":"first","affiliation":[{"name":"Dr. Ruth KM Pfau Civil Hospital","place":["Karachi, Pakistan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laila Tul","family":"Qadar","sequence":"additional","affiliation":[{"name":"St. Vincent\u2019s Medical Center","place":["Bridgeport, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jawad","family":"Ahmed","sequence":"additional","affiliation":[{"name":"Northwest Health","place":["Valparaiso, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zohaib","family":"Yousaf","sequence":"additional","affiliation":[{"name":"Drexel University School of Medicine","place":["West Reading, USA"]},{"name":"Reading Hospital","place":["West Reading, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Afsana Ansari","family":"Shaik","sequence":"additional","affiliation":[{"name":"Mayo Clinic","place":["Rochester, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6705-2030","authenticated-orcid":false,"given":"Muhammad Sohaib","family":"Asghar","sequence":"additional","affiliation":[{"name":"Mayo Clinic","place":["Rochester, USA"]},{"name":"AdventHealth","place":["Sebring, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2025,6,26]]},"reference":[{"key":"e_1_3_7_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.heliyon.2024.e26368"},{"key":"e_1_3_7_4_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V98.10.3113"},{"key":"e_1_3_7_5_1","doi-asserted-by":"publisher","DOI":"10.3389\/fphys.2021.735543"},{"key":"e_1_3_7_6_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2023011477"},{"key":"e_1_3_7_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(22)01337-X"},{"key":"e_1_3_7_8_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2022015403"},{"key":"e_1_3_7_9_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2023012467"},{"key":"e_1_3_7_10_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2023-181213"},{"key":"e_1_3_7_11_1","unstructured":"Research C for DE and. FDA approves treatment for anemia in adults with rare inherited disorder FDA.[Internet]. 2022 [cited 2024 Oct 19]."},{"key":"e_1_3_7_12_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpdd.1058"},{"key":"e_1_3_7_13_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n71"},{"key":"e_1_3_7_14_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2116634"},{"key":"e_1_3_7_15_1","unstructured":"Pharmaceuticals A. Inc. A phase 3 Double-blind randomized placebo-controlled multicenter study evaluating the efficacy and safety of mitapivat in subjects with transfusion-dependent alpha- or Beta-thalassemia (ENERGIZE-T).clinicaltrials gov; Report No.: nCT04770779. Available from 2024 [cited 2025 Mar 28]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT04770779"},{"key":"e_1_3_7_16_1","unstructured":"Baldwin C Pandey J Olarewaju O. Hemolytic anemia StatPearls.[Internet]. Treasure Island (FL): StatPearls Publishing; 2024 [cited 2024 Oct 19]. Available from: http:\/\/www.ncbi.nlm.nih.gov\/books\/NBK558904\/"},{"key":"e_1_3_7_17_1","unstructured":"The Cochrane Collaboration\u2019s tool for assessing risk of bias in randomised trials | the BMJ [Internet]. [cited 2024 Oct 19]. Available from: https:\/\/www.bmj.com\/content\/343\/bmj.d5928.long"},{"key":"e_1_3_7_18_1","unstructured":"Pharmaceuticals A. Inc. A phase 2\/3 Double-blind randomized placebo-controlled multicenter study to evaluate the efficacy and safety of mitapivat in subjects with sickle cell disease clinicaltrials gov [Internet]. Report No.: nCT05031780. Available from cited 2025 Mar 28]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT05031780"},{"key":"e_1_3_7_19_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.i4919"},{"key":"e_1_3_7_20_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2022.282614"},{"key":"e_1_3_7_21_1","unstructured":"Pharmaceuticals A. Inc. A phase 3 multicenter randomized Double-blind placebo-controlled study to evaluate the efficacy and safety of mitapivat in pediatric subjects with pyruvate kinase deficiency who are regularly transfused followed by a 5-year open-label extension period [Internet]. clinicaltrials gov; Report No.: nCT05144256. Available from 2024 [cited 2025 Mar 28]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT05144256"},{"key":"e_1_3_7_22_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1902678"},{"key":"e_1_3_7_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(22)00214-9"},{"key":"e_1_3_7_24_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2023011743"},{"key":"e_1_3_7_25_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00520-022-06883-0"},{"key":"e_1_3_7_26_1","unstructured":"Pharmaceuticals A. Inc. A phase 3 multicenter randomized Double-blind placebo-controlled study to evaluate the efficacy and safety of mitapivat in pediatric subjects with pyruvate kinase deficiency who are not regularly transfused followed by a 5-year open-label extension period [Internet]. clinicaltrials gov; Report No.: nCT05175105. Available from 2025 [cited 2025 Mar 28]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT05175105"},{"key":"e_1_3_7_27_1","unstructured":"Heart N. Lung and blood institute (NHLBI). Observational study investigating the mechanistic effects of mitapivat in subjects with sickle cell disease [Internet]. Report No.: nCT05675436. Available from cited 2025 Mar 30]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT05675436"},{"key":"e_1_3_7_28_1","unstructured":"Successes and challenges in clinical gene therapy - PMC [Internet]. [cited 2024 Oct 19]. Available from: https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC10678346\/"},{"key":"e_1_3_7_29_1","unstructured":"National Heart lung and blood institute (NHLBI). Evaluation of the safety Tolerability pharmacokinetics and pharmacodynamics of long-term mitapivat dosing in subjects with stable sickle cell disease: an extension of a phase I Pilot study of mitapivat [Internet]. clinicaltrials; Report No.: nCT04610866. Available from 2025 [cited 2025 Mar 28]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT04610866"},{"key":"e_1_3_7_30_1","unstructured":"Pharmaceuticals A. Inc. A phase 2 open-label multicenter study of mitapivat in subjects with sickle cell disease and nephropathy (RESIST).clinicaltrials gov; Report No.: nCT06286046. Available from 2025 [cited 2025 Mar 30]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT06286046"}],"container-title":["Expert Review of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/17474086.2025.2522295","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T10:23:52Z","timestamp":1754043832000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/17474086.2025.2522295"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,26]]},"references-count":28,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2025,8,3]]}},"alternative-id":["10.1080\/17474086.2025.2522295"],"URL":"https:\/\/doi.org\/10.1080\/17474086.2025.2522295","relation":{},"ISSN":["1747-4086","1747-4094"],"issn-type":[{"value":"1747-4086","type":"print"},{"value":"1747-4094","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,26]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ierr20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ierr20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2024-12-31","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-06-16","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-06-26","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}